ViroPharma Up On Data For Hepatitis C Drug

[Guest guest]

ViroPharma Up On Data For Hepatitis C Drug

http://www.therapeuticsdaily.com/news/summary.cfm?id=1060735 & channelID=31

ViroPharma late Monday reported preliminary data from a Phase 1b study of

HCV-796 in combination with a medication called pegylated interferon in

people with hepatitis C infection who hadn't been previously treated.

ViroPharma said the combination therapy was superior to pegylated interferon

alone in reducing the virus. After 14 days of treatment, the combination

therapy had a mean viral reduction of between 3.3 and 3.5 log10, a

measurement used for viral loads.

Summary

• (VPHM) shares jumped 11.5% Tuesday after the drug company reported what it

called positive data from small, early-stage studies of an experimental

treatment for Hepatitis C.

• The Exton, Pa., company is developing HCV-796 with pharmaceutical giant

Wyeth (WYE) of Madison, N.J. HCV-796 is a potential treatment for hepatitis

C, a liver disease caused by a virus.

• ViroPharma late Monday reported preliminary data from a Phase 1b study of

HCV-796 in combination with a medication called pegylated interferon in

people with hepatitis C infection who hadn't been previously treated.

• Pegylated interferon is a standard treatment for hepatitis C and is sold

under the brands Pegasys by Roche Holding AG (RHHBY) and Peg-Intron by

Schering-Plough Corp.

• (SGP).

• ViroPharma said the combination therapy was superior to pegylated

interferon alone in reducing the virus.

• After 14 days of treatment, the combination therapy had a mean viral

reduction of between 3.3 and 3.5 log10, a measurement used for viral loads.

• In comparison, pegylated interferon alone had a viral reduction of 1.7

log10, ViroPharma said.

_________________________________________________________________

Get real-time traffic reports with Windows Live Local Search

http://local.live.com/default.aspx?v=2 & cp=42.336065~-109.392273 & style=r & lvl=4 & sc\

ene=3712634 & trfc=1

[Guest guest]

ViroPharma Up On Data For Hepatitis C Drug

http://www.therapeuticsdaily.com/news/summary.cfm?id=1060735 & channelID=31

ViroPharma late Monday reported preliminary data from a Phase 1b study of

HCV-796 in combination with a medication called pegylated interferon in

people with hepatitis C infection who hadn't been previously treated.

ViroPharma said the combination therapy was superior to pegylated interferon

alone in reducing the virus. After 14 days of treatment, the combination

therapy had a mean viral reduction of between 3.3 and 3.5 log10, a

measurement used for viral loads.

Summary

• (VPHM) shares jumped 11.5% Tuesday after the drug company reported what it

called positive data from small, early-stage studies of an experimental

treatment for Hepatitis C.

• The Exton, Pa., company is developing HCV-796 with pharmaceutical giant

Wyeth (WYE) of Madison, N.J. HCV-796 is a potential treatment for hepatitis

C, a liver disease caused by a virus.

• ViroPharma late Monday reported preliminary data from a Phase 1b study of

HCV-796 in combination with a medication called pegylated interferon in

people with hepatitis C infection who hadn't been previously treated.

• Pegylated interferon is a standard treatment for hepatitis C and is sold

under the brands Pegasys by Roche Holding AG (RHHBY) and Peg-Intron by

Schering-Plough Corp.

• (SGP).

• ViroPharma said the combination therapy was superior to pegylated

interferon alone in reducing the virus.

• After 14 days of treatment, the combination therapy had a mean viral

reduction of between 3.3 and 3.5 log10, a measurement used for viral loads.

• In comparison, pegylated interferon alone had a viral reduction of 1.7

log10, ViroPharma said.

_________________________________________________________________

Get real-time traffic reports with Windows Live Local Search

http://local.live.com/default.aspx?v=2 & cp=42.336065~-109.392273 & style=r & lvl=4 & sc\

ene=3712634 & trfc=1